SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis

FRA:56S1 • FR0013154002

170.1 EUR
-4.75 (-2.72%)
Last: Feb 16, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Taking everything into account, 56S1 scores 4 out of 10 in our fundamental rating. 56S1 was compared to 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. 56S1 is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • 56S1 had positive earnings in the past year.
  • In the past year 56S1 had a positive cash flow from operations.
  • Of the past 5 years 56S1 4 years were profitable.
  • 56S1 had a positive operating cash flow in 4 of the past 5 years.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.36%, 56S1 is doing worse than 61.11% of the companies in the same industry.
  • The Return On Equity of 56S1 (6.55%) is comparable to the rest of the industry.
  • Looking at the Return On Invested Capital, with a value of 5.94%, 56S1 is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for 56S1 is in line with the industry average of 9.81%.
  • The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 3.36%
ROE 6.55%
ROIC 5.94%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • 56S1 has a Profit Margin of 8.98%. This is in the better half of the industry: 56S1 outperforms 61.11% of its industry peers.
  • 56S1's Profit Margin has declined in the last couple of years.
  • With a decent Operating Margin value of 16.63%, 56S1 is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • In the last couple of years the Operating Margin of 56S1 has declined.
  • Looking at the Gross Margin, with a value of 45.64%, 56S1 is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
  • 56S1's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.63%
PM (TTM) 8.98%
GM 45.64%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • 56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • 56S1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • 56S1 has an Altman-Z score of 3.89. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
  • 56S1 has a better Altman-Z score (3.89) than 72.22% of its industry peers.
  • 56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
  • The Debt to FCF ratio of 56S1 (6.84) is comparable to the rest of the industry.
  • 56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
  • 56S1 has a Debt to Equity ratio of 0.50. This is in the better half of the industry: 56S1 outperforms 61.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 6.84
Altman-Z 3.89
ROIC/WACC0.65
WACC9.12%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
  • 56S1's Current ratio of 1.05 is on the low side compared to the rest of the industry. 56S1 is outperformed by 61.11% of its industry peers.
  • A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
  • 56S1 has a Quick ratio of 0.50. This is in the lower half of the industry: 56S1 underperforms 72.22% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.5
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.71% over the past year.
  • Measured over the past 5 years, 56S1 shows a small growth in Earnings Per Share. The EPS has been growing by 1.13% on average per year.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.78%

3.2 Future

  • 56S1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.33% yearly.
  • 56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.83% yearly.
EPS Next Y21.28%
EPS Next 2Y21.44%
EPS Next 3Y22.34%
EPS Next 5Y18.33%
Revenue Next Year8.64%
Revenue Next 2Y9.88%
Revenue Next 3Y11.44%
Revenue Next 5Y10.83%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 38.66, 56S1 can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 72.22% of the companies are valued more cheaply.
  • When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (27.19), we can say 56S1 is valued slightly more expensively.
  • A Price/Forward Earnings ratio of 31.87 indicates a quite expensive valuation of 56S1.
  • Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than 66.67% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of 56S1 to the average of the S&P500 Index (28.06), we can say 56S1 is valued inline with the index average.
Industry RankSector Rank
PE 38.66
Fwd PE 31.87
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 56S1 is valued a bit more expensive than 66.67% of the companies in the same industry.
  • 56S1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 44.2
EV/EBITDA 23.28
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as 56S1's earnings are expected to grow with 22.34% in the coming years.
PEG (NY)1.82
PEG (5Y)34.27
EPS Next 2Y21.44%
EPS Next 3Y22.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • 56S1 has a yearly dividend return of 0.41%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.45, 56S1 pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, 56S1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.41%

5.2 History

  • The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1

5.3 Sustainability

  • 56S1 pays out 25.37% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.37%
EPS Next 2Y21.44%
EPS Next 3Y22.34%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SARTORIUS STEDIM BIOTECH

FRA:56S1 (2/16/2026, 7:00:00 PM)

170.1

-4.75 (-2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)N/A
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.56B
Revenue(TTM)N/A
Net Income(TTM)264.50M
Analysts78.95
Price Target246.85 (45.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.41%
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.37%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)2.56%
PT rev (3m)1.96%
EPS NQ rev (1m)-1.66%
EPS NQ rev (3m)2.5%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)0.65%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.38%
Valuation
Industry RankSector Rank
PE 38.66
Fwd PE 31.87
P/S 5.62
P/FCF 44.2
P/OCF 22.66
P/B 4.1
P/tB N/A
EV/EBITDA 23.28
EPS(TTM)4.4
EY2.59%
EPS(NY)5.34
Fwd EY3.14%
FCF(TTM)3.85
FCFY2.26%
OCF(TTM)7.51
OCFY4.41%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.82
PEG (5Y)34.27
Graham Number64.07
Profitability
Industry RankSector Rank
ROA 3.36%
ROE 6.55%
ROCE 7.46%
ROIC 5.94%
ROICexc 6.26%
ROICexgc 21.64%
OM 16.63%
PM (TTM) 8.98%
GM 45.64%
FCFM 12.71%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 6.84
Debt/EBITDA 2.5
Cap/Depr 112.98%
Cap/Sales 12.09%
Interest Coverage 3.09
Cash Conversion 90.75%
Profit Quality 141.63%
Current Ratio 1.05
Quick Ratio 0.5
Altman-Z 3.89
F-Score8
WACC9.12%
ROIC/WACC0.65
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
EPS Next Y21.28%
EPS Next 2Y21.44%
EPS Next 3Y22.34%
EPS Next 5Y18.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.78%
Revenue Next Year8.64%
Revenue Next 2Y9.88%
Revenue Next 3Y11.44%
Revenue Next 5Y10.83%
EBIT growth 1Y25.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y26.76%
FCF growth 1Y219.35%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.98%
OCF growth 3Y5.11%
OCF growth 5Y21.32%

SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.


Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.


How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for 56S1 stock?

The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 38.66 and the Price/Book (PB) ratio is 4.1.


What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?

The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 21.28% in the next year.